Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Diabetic Foot Ulcer Biologics Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The diabetic foot ulcer biologics market size has shown robust expansion in recent years. It will grow from $1.93 billion in 2025 to $2.09 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The market’s growth in previous periods can be attributed to elements such as the limited availability of advanced biologics, a reliance on conventional wound care treatments, the increasing prevalence of diabetes-related foot ulcers, rising adoption within hospitals and clinics, and the absence of standardized treatment protocols.
The diabetic foot ulcer biologics market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $2.87 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.3%. This projected growth can be primarily attributed to technological advancements in stem cell and gene therapy, along with growing investment in tissue engineering research. Further contributing factors include the increasing adoption of autologous and allogeneic cell-based biologics, the expansion of long-term care and ambulatory surgical centers, and a rising awareness of personalized wound care solutions. Significant trends during the forecast period involve the increasing uptake of stem cell and gene therapies, a rising use of collagen-based biologics for wound healing, the expansion of skin substitutes in diabetic foot ulcer management, the integration of advanced tissue engineering techniques, and an intensified focus on personalized and targeted biologics treatments.
Get A Free Sample Report With In-Depth Market Insights:
Diabetic Foot Ulcer Biologics Market Development Factors: What’s Supporting Demand?
The increasing incidence of diabetes is projected to fuel the expansion of the diabetic foot ulcer biologics market in the future. This chronic ailment is defined by elevated blood sugar levels, occurring when the body either fails to produce insulin or cannot utilize it properly. The growth in diabetes cases primarily stems from inactive lifestyles, which, in turn, generates a greater need for sustained care options that manage blood sugar efficiently without significantly disrupting daily routines. Diabetic foot ulcer biologics play a crucial role in diabetes management by speeding up wound recovery, averting infections, and mitigating issues associated with persistent foot ulcers. As an illustration, in April 2025, data from the International Diabetes Federation (IDF) Atlas, a Belgium-based non-profit body, indicated that in 2024, 9.5 million of the 589 million adults with diabetes had type 1, and this figure is anticipated to climb to 853 million by 2050. Consequently, the escalating occurrence of diabetes is propelling the development of the diabetic foot ulcer biologics market.
Diabetic Foot Ulcer Biologics Market Segments: Where Is Growth Concentrated?
The diabetic foot ulcer biologics market covered in this report is segmented –
1) By Type: Growth Factors, Skin Substitutes, Collagen-Based Biologics, Cell-Based Biologics
2) By Indication: Neuro-Ischemic Ulcers, Neuropathic Diabetic Foot Ulcer, Ischemic Diabetic Foot Ulcer
3) By Technology: Gene Therapy, Stem Cell Therapy, Tissue Engineering
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Long-Term Care Settings, Other End Users
Subsegments:
1) By Growth Factors: Platelet-Derived Growth Factor, Epidermal Growth Factor, Fibroblast Growth Factor, Vascular Endothelial Growth Factor
2) By Skin Substitutes: Synthetic Skin Substitutes, Biological Skin Substitutes, Composite Skin Substitutes
3) By Collagen-Based Biologics: Bovine-Derived Collagen, Porcine-Derived Collagen, Human-Derived Collagen
4) By Cell-Based Biologics: Autologous Cell-Based Biologics, Allogeneic Cell-Based Biologics, Stem Cell-Based Biologics
Diabetic Foot Ulcer Biologics Market Transformation Trends: What Innovations Are Driving Change?
Major companies operating in the diabetic foot ulcer biologics market are concentrating their research and development efforts on biologic therapies, such as placental-derived allograft, to improve wound healing, decrease complications, and enhance patient outcomes in the management of chronic foot ulcers. A placental-derived allograft is a biological tissue graft derived from donated human placental tissues, including the amnion or chorion, and applied in medical settings to foster healing, diminish inflammation, and support tissue regeneration. For example, in January 2025, BioStem Technologies Inc., a US-based pharmaceutical company, commenced a clinical trial utilizing its BioREtain technology with Vendaje for the treatment of diabetic foot ulcers. This study evaluates Vendaje combined with standard care versus standard care solely to demonstrate its effectiveness in promoting the healing of non-healing diabetic foot ulcers. It also features a follow-up phase to assess the long-term durability and stability of healed wounds, ensuring enduring treatment success and reducing the likelihood of ulcer recurrence.
Diabetic Foot Ulcer Biologics Market Key Participants And Competitive Landscape
Major companies operating in the diabetic foot ulcer biologics market are Smith & Nephew plc, Integra LifeSciences Holdings Corp., Organogenesis Holdings Inc., MIMEDX Group Inc., LifeNet Health, Aroa Biosurgery, Tissue Regenix Group plc, Stempeutics Research, ACell Inc.,
View The Full Diabetic Foot Ulcer Biologics Market Report:
Diabetic Foot Ulcer Biologics Market Regional Analysis And Leading Geography
North America was the largest region in the diabetic foot ulcer biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic foot ulcer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
